ULTRAGENYX DRNULTRAGENYX DRNULTRAGENYX DRN

ULTRAGENYX DRN

No trades
See on Supercharts

Key stats

Market capitalization
‪17.62 B‬BRL
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
−0.36

About Ultragenyx Pharmaceutical Inc.

CEO
Emil D. Kakkis
Headquarters
Novato
Founded
2010
ISIN
BRR2ARBDR006
FIGI
BBG014XM9CJ9
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.